Biocryst Pharmaceuticals (BCRX) Net Margin Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) Net Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 948.00 |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | -491.00 |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 83.00 |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | -94.00 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -990.00 |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -604.00 |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 1,312.00 |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.45 Bn | 2.10 Bn | 214.41 Mn | 12,723.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12,723.00 |
| Mar 31, 2026 | -38,393.00 |
| Dec 31, 2025 | 3.48 Mn |
| Sep 30, 2025 | 6,417.00 |
| Jun 30, 2025 | 9,293.00 |
| Mar 31, 2025 | 14,864.00 |
| Dec 31, 2024 | 1,733.00 |
| Sep 30, 2024 | 13,145.00 |
| Jun 30, 2024 | 7,487.00 |
| Mar 31, 2024 | 29,915.00 |
| Dec 31, 2023 | 160,079.00 |
| Sep 30, 2023 | 71,387.00 |
| Jun 30, 2023 | 125,560.00 |
| Mar 31, 2023 | 70,162.00 |
| Dec 31, 2022 | -8,184.00 |
| Sep 30, 2022 | 207,012.00 |
| Jun 30, 2022 | 249,347.00 |
| Mar 31, 2022 | 38,578.00 |
| Dec 31, 2021 | 88,780.00 |
| Sep 30, 2021 | 193,552.00 |